Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Operations: 2022-2024

Historic Cash from Operations for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$50.6 million.

  • Orchestra BioMed Holdings' Cash from Operations fell 6.20% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.2 million, marking a year-over-year decrease of 25.50%. This contributed to the annual value of -$50.6 million for FY2024, which is 9.61% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Cash from Operations stood at -$50.6 million for FY2024, which was down 9.61% from -$46.1 million recorded in FY2023.
  • Orchestra BioMed Holdings' 5-year Cash from Operations high stood at -$29.3 million for FY2022, and its period low was -$50.6 million during FY2024.
  • Over the past 3 years, Orchestra BioMed Holdings' median Cash from Operations value was -$46.1 million (recorded in 2023), while the average stood at -$42.0 million.
  • Data for Orchestra BioMed Holdings' Cash from Operations shows a maximum YoY slumped of 57.49% (in 2023) over the last 5 years.
  • Orchestra BioMed Holdings' Cash from Operations (Yearly) stood at -$29.3 million in 2022, then slumped by 57.49% to -$46.1 million in 2023, then dropped by 9.61% to -$50.6 million in 2024.